TY - JOUR T1 - Extra-abdominal Metastases From Epithelial Ovarian Carcinoma: an Analysis of 20 Cases JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 611-614 LP - 611-614 DO - 10.1111/IGC.0b013e3181a416d0 VL - 19 IS - 4 AU - Bei Cheng AU - Weiguo Lu AU - Wan Xiaoyun AU - Chen Yaxia AU - Xing Xie Y1 - 2009/04/01 UR - http://ijgc.bmj.com/content/19/4/611-614.abstract N2 - Objective: To investigate the clinicopathologic risk factors associated with extra-abdominal metastases in epithelial ovarian carcinoma patients and to determine prognostic factors associated with survival.Methods: A retrospective chart review was conducted on 20 cases of epithelial ovarian carcinoma patients with extra-abdominal metastases and 645 cases of epithelial ovarian carcinoma patients without extra-abdominal metastases treated at our unit between 1993 and 2007.Results: A total of 25 extra-abdominal metastatic sites were diagnosed in 20 patients. Sites of metastases were lung, n = 7; skin, n = 6; pleura, n = 5; brain, n = 3; mediastinal lymph node, n = 3; and bone, n = 1. Median interval time between diagnosis of epithelial ovarian carcinoma and documentation of metastatic disease of these 18 patients was 16 months. Median survival time after extra-abdominal metastases was 11 months. In a univariate analysis, Karnofsky performance status (KPS), clinical stage, and sensitivity of primary chemotherapy were the risk factors significantly associated with extra-abdominal metastases. These risk factors remained significant in multivariate analysis. In univariate analysis KPS, sensitivity of primary chemotherapy, metastatic site, and systemic therapy after diagnosis of extra-abdominal metastases were the factors significantly associated with survival.Conclusion: Some clinicopathologic risk factors may associate with extra-abdominal metastases. Prognosis after documentation of extra-abdominal metastases from epithelial ovarian carcinoma is poor. The important prognostic factors associated with survival are KPS, sensitivity of primary chemotherapy, metastatic site, and systemic therapy after diagnosis of extra-abdominal metastases. ER -